Designs of NKG2D-based immunotherapeutics for cancer

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Natural killer group 2 D (NKG2D) is an activating receptor on NK cells, crucial for cancer immunosurveillance.
• NKG2D ligands are upregulated on various cancer cells, making NKG2D a target for cancer immunotherapy.
• Human and mouse NKG2D receptors exhibit distinct signaling pathways (DAP10 vs. DAP10/12), influencing effector functions.

Purpose of the Study:

• To review and compare various designs of NKG2D-based chimeric antigen receptors (CARs) and antibodies.
• To analyze the advantages and disadvantages of different NKG2D-based immunotherapeutic strategies.
• To summarize the preclinical and clinical investigation of these NKG2D-based therapies in solid tumors.

Main Methods:

• Literature review of published studies on NKG2D-based CARs and antibodies.
• Comparative analysis of different CAR and antibody designs and their components (e.g., extracellular, full-length domains).
• Examination of preclinical cancer models and clinical trial data for NKG2D-based therapies.

Main Results:

• NKG2D CARs and antibodies have been developed using various NKG2D domains.
• Preclinical studies predominantly focus on solid tumors, with T cells and NK cells as effector platforms.
• Differences in human and mouse NKG2D signaling impact effector functions like IFN-γ production and cytotoxicity.

Conclusions:

• NKG2D-based CARs and antibodies represent a promising area of cancer immunotherapy research.
• Understanding the distinct signaling pathways is crucial for optimizing therapeutic strategies.
• Further investigation in preclinical and clinical settings is warranted to assess the full potential of NKG2D-based treatments.